Collaboration - September 6, 2021
University of Helsinki collaborates with Boehringer Ingelheim
The Neuroscience Center of the University of Helsinki has entered into a research collaboration with Boehringer Ingelheim on human translational models. The target of the collaboration is to accelerate innovative gene therapy for brain diseases with high medical need. The collaborators will work on improving human brain organoid models to study central nervous system (CNS) […]
Agreement - August 6, 2021
Nanoform and Boehringer Ingelheim execute master services agreement
The two companies have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space. The aim with the agreement is to solve the challenge of poor bioavailability and solubility in new drug candidates. “Wider uptake of the latest technological innovations is essential to address the low success rates for new […]
Agreement - September 4, 2019
Zealand Pharma and Boehringer Ingelheim initiate Phase 2 development of BI 456906
Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. Potential as […]
Collaboration - September 8, 2017
Danish Gubra collaborates with Boehringer Ingelheim
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. It further […]
In a new job - February 13, 2017
New Swedish CEO at Boehringer Ingelheim
Andrea Sambattit has been appointed new CEO of the Swedish subsidiary of Boehringer Ingelheim. The last 17 years Sambatti has been working in different fields of the pharmceutical industry, including primary as well as speciaist care with experience from sales, marketing and leadership. She started her career at Boehringer Ingeheim Brazil in 2009, responsible for […]
Agreement - August 29, 2016
Saniona, Boehringer Ingelheim in agreement
Boehringer Ingelheim and Saniona, a Nordic biotech company in the field of ion channel drug discovery, today announced that they have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia. Saniona may receive up to €90 million in milestone payments including an upfront payment of […]
